UCB SA (UCBJY)
| Previous Close | 64.86 |
| Open | 64.47 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 64.22 - 64.49 |
| 52 Week Range | 34.85 - 67.30 |
| Volume | |
| Avg. Volume | 12,943 |
| Market Cap | 24.783B |
| Beta (5Y Monthly) | 0.40 |
| PE Ratio (TTM) | 67.88 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 0.72 (1.12%) |
| Ex-Dividend Date | Apr 26, 2024 |
| 1y Target Est | N/A |
- PR Newswire
UCB presents new data highlighting developments across expansive neurology portfolio at 76th American Academy of Neurology (AAN) Annual Meeting
UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today announced the latest research from its expansive neurology portfolio and pipeline to be presented at the 76th American Academy of Neurology (AAN) Annual Meeting, April 13-18, 2024, in Denver, Colorado, USA.
- PR Newswire
UCB Launches Make HStory, an Educational Campaign Offering Resources and Support for Those Living with Hidradenitis Suppurativa
UCB, a global biopharmaceutical company, today announced the launch of Make HStory, an educational campaign that provides tools and resources for those living with hidradenitis suppurativa (HS) and their dermatologists.
- PR Newswire
FDA Accepts Supplemental Biologics License Applications for BIMZELX® (bimekizumab-bkzx) for Moderate-to-Severe Hidradenitis Suppurativa and Additional 2mL Device Presentations
UCB, a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for BIMZELX® (bimekizumab-bkzx), an IL-17A and IL-17F inhibitor, for the treatment of adults with moderate-to-severe hidradenitis suppurativa (HS). In addition, a second sBLA for the BIMZELX 2mL device presentations has also been accepted.
